Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 

Slides:



Advertisements
Similar presentations
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Advertisements

Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.
Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)
DR ABUL AZIM CONSULTANT IN ELDERLY MEDICINE & STROKE STROKE AND ATRIAL FIBRILLATION AND THE ROLE OF THE NOAC.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Atrial Fibrillation Management Past, Present and Future
1 MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical.
Managing Patients Who Cannot Take Anticoagulants Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director,
Update in ESC: Dabigatran among OAC
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
1 Dr. Mario Fitz Maurice Electrofisiología Cardíaca Hospital Rivadavia AF AC Anticoagulation in Atrial Fibrillation.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC/HRS Guideline for the Management of.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA/ESC 2006 Guidelines for the Management of.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
The patient with atrial fibrillation who needs PCI
CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation 
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Volume 149, Issue 6, Pages (June 2016)
From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation  Chern-En Chiang, Tsu-Juey.
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
Antithrombotic Therapy in Atrial Fibrillation
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
Efficacy and Safety of Dabigatran vs
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention 
Anticoagulation in Atrial Fibrillation
The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines  Laurent Macle, MD,
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Novel oral anticoagulants in comparison with warfarin
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control 
Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation  Lena Rivard, MD, MSc, Paul Khairy, MD,
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy 
Fibrillazione atriale
Selecting NOACs for High-Risk Patients
Left atrial appendage closure: A new technique for clinical practice
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials  Giulia Renda, MD, PhD, Marta.
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco.
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,
Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD 
Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials  Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,
The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines  Laurent Macle, MD,
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease  Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,
2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Atul Verma, MD, John A. Cairns, MD, L.
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Jason G. Andrade, MD, Atul Verma, MD,
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy 
5 Good Minutes on Atrial Fibrillation-related Stroke
(p for noninferiority = 0.01)
Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.
Erratum Canadian Journal of Cardiology
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management  Anne M. Gillis, MD, FRCPC, Atul Verma, MD, FRCPC, Mario.
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco.
Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,
Figure 8. Stroke prevention strategy in patients with AF
Gianluigi Savarese et al. JCHF 2016;4:
Forest plot illustrating the risk ratio of major bleeding
Presenter Disclosure Information
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter  John A. Cairns, MD, FRCPC, Stuart Connolly, MD, FRCPC, Sean McMurtry, MD, PhD, FRCPC, Michael Stephenson, MD, FCFP, Mario Talajic, MD, FRCPC  Canadian Journal of Cardiology  Volume 27, Issue 1, Pages 74-90 (January 2011) DOI: 10.1016/j.cjca.2010.11.007 Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 1 Randomized controlled trials (RCTs) of adjusted-dose warfarin (or other vitamin K antagonist in a small proportion of patients) vs placebo or no treatment. Point estimates of the relative risk reductions of stroke (ischemic plus hemorrhagic) with their associated 95% CIs are depicted for 5 trials of primary prevention and 1 of secondary prevention. The overall relative risk reduction is 64% (95% CI, 49%-74%). AFASAK, Atrial Fibrillation, ASpirin, AntiKoagulation; SPAF, Stroke Prevention in Atrial Fibrillation; BAATAF, Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation; SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation; EAFT, European Atrial Fibrillation Trial. Reprinted from Hart RG et al26 with permission from Ann Intern Med. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 2 Randomized controlled trials (RCTs) of aspirin vs placebo or no treatment. Point estimates of the relative risk reductions of stroke (ischemic plus hemorrhagic) with their associated 95% CIs are depicted for 4 trials of primary prevention and 3 of secondary prevention. The overall relative risk reduction is 19% (95% CI, −1% to 35%). AFASAK, Atrial Fibrillation, ASpirin, AntiKoagulation; SPAF, Stroke Prevention in Atrial Fibrillation; EAFT, European Atrial Fibrillation Trial; ESPS, European Stroke Prevention Study; LASAF, Low-dose Aspirin, Stroke, Atrial Fibrillation; UK-TIA, United Kingdom Transient Ischemic Attack; JAST, Japan Atrial fibrillation Stroke Trial. Reprinted from Hart RG et al26 with permission from Ann Intern Med. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 3 Randomized trials of adjusted-dose warfarin (or other vitamin K antagonist in a small proportion of patients) vs aspirin. Point estimates of the relative risk reductions of stroke (ischemic or hemorrhagic) with their associated 95% CIs are depicted for 7 trials of primary prevention and 1 of secondary prevention. The overall relative risk reduction is 39% (95% CI, 19%-53%). AFASAK, Atrial Fibrillation, ASpirin, AntiKoagulation; BAFTA, Birmingham Atrial Fibrillation Treatment of the Aged; Chinese ATAFS, Chinese Antithrombotic Therapy in Atrial Fibrillation; EAFT, European Atrial Fibrillation Trial; PATAF, Prevention of Arterial Thromboembolism in Atrial Fibrillation; SPAF, Stroke Prevention in Atrial Fibrillation. Reprinted from Hart RG et al27 with permission from Ann Intern Med. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 4 Cumulative hazard rates (y-axis) vs time in years (x-axis) for the primary outcome of stroke (ischemic or hemorrhagic) or systemic embolism, according to treatment group (dabigatran 150 mg twice daily, dabigatran 110 mg twice daily, or warfarin [INR 2-3]). RR, relative risk. Reprinted from Connolly SJ, et al36 with permission from N Engl J Med, © Massachusetts Medical Society. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 5 A summary of our recommendations for thromboembolic management guided by the CHADS2 score. See Tables 1 and 2 for definitions of CHADS2 and HAS-BLED. OAC, oral anticoagulant. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 6 A summary of our recommended strategies for antithrombotic therapy in conjunction with cardioversion. CHADS2, please see Table 1; INR, international normalized ratio; NSR, normal sinus rhythm; OAC, oral anticoagulant; TEE, transesophageal echocardiography; TIA, transient ischemic attack. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 7 A summary of our recommendations for antithrombotic management in settings of coronary artery disease. ACS, acute coronary syndrome; CAD, coronary artery disease; CHADS2, see Table 1; OAC, oral anticoagulant; PCI, percutaneous coronary intervention. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions

Figure 8 A summary of our recommendations for management of antithrombotic therapies in patients undergoing surgical or diagnostic procedures with a risk of major bleeding. AF, atrial fibrillation; CHADS2, see Table 1; INR, international normalized ratio; LMWH, low molecular weight heparin; OAC, oral anticoagulant; TIA, transient ischemic attack; UFH, ultrafractionated heparin. Canadian Journal of Cardiology 2011 27, 74-90DOI: (10.1016/j.cjca.2010.11.007) Copyright © 2011 Canadian Cardiovascular Society Terms and Conditions